Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus

Pulmonary hypertension with pathologicalchanges similar to those observed in primary pulmonary hypertensionoccurs in patients with systemic lupus erythematosus (SLE). Theefficacy of chronic epoprostenol therapy in SLE has not been welldescribed. The objective of this paper is to describe our experie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Chest 2000-01, Vol.117 (1), p.14-18
Hauptverfasser:	Robbins, Ivan M., Gaine, Sean P., Schilz, Robert, Tapson, Victor F., Rubin, Lewis J., Loyd, James E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antihypertensive Agents - therapeutic use Biological and medical sciences Cardiac Catheterization Cardiovascular disease Case-Control Studies Complications and side effects Congenital diseases CREST = variant of sclerodermacharacterized by calcinosis, Raynaud's phenomenon, esophageal motilitydisorders, sclerodactyly, and telangiectasia Drug therapy epoprostenol Epoprostenol - therapeutic use Female Heart Hemodynamics Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - etiology Hypertension, Pulmonary - physiopathology Intubation Lupus Lupus Erythematosus, Systemic - complications Medical sciences mPAP = mean pulmonaryartery pressure Nitric oxide PAP = pulmonary artery pressure Patients Pharmacology. Drug treatments PPH = primarypulmonary hypertension Pulmonary arteries Pulmonary hypertension Pulmonary Wedge Pressure - drug effects PVR = pulmonary vascular resistance Respiratory system Scleroderma SLE = systemic lupus erythematosus Systemic lupus erythematosus Treatment Outcome Vascular Resistance - drug effects Vasodilation - drug effects Veins & arteries
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!